Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 5;98(14):576-582.
doi: 10.1212/WNL.0000000000200240. Epub 2022 Feb 21.

COVID-19-Related Outcomes in Primary Mitochondrial Diseases: An International Study

Collaborators, Affiliations

COVID-19-Related Outcomes in Primary Mitochondrial Diseases: An International Study

Chiara Pizzamiglio et al. Neurology. .

Abstract

Background and objectives: To identify factors associated with severe coronavirus disease 2019 (COVID-19), defined by hospitalization status, in patients with primary mitochondrial diseases (PMDs), thereby enabling future risk stratification and informed management decisions.

Methods: We undertook a cross-sectional, international, registry-based study. Data were extracted from the International Neuromuscular COVID-19 Database and collected between May 1, 2020, and May 31, 2021. The database included subjects with (1) PMD diagnosis (any age), clinically/histopathologically suspected and/or genetically confirmed; and (2) COVID-19 diagnosis classified as "confirmed", "probable", or "suspected" based on World Health Organization definitions. The primary outcome was hospitalization because of COVID-19. We collected demographic information, smoking status, coexisting comorbidities, outcomes after COVID-19 infection, and PMD genotype-phenotype. Baseline status was assessed using the modified Rankin scale (mRS) and the Newcastle Mitochondrial Disease Adult Scale (NMDAS).

Results: Seventy-nine subjects with PMDs from 10 countries were included (mean age 41.5 ± 18 years): 25 (32%) were hospitalized, 48 (61%) recovered fully, 28 (35%) improved with sequelae, and 3 (4%) died. Statistically significant differences in hospitalization status were observed in baseline status, including the NMDAS score (p = 0.003) and mRS (p = 0.001), presence of respiratory dysfunction (p < 0.001), neurologic involvement (p = 0.003), and more than 4 comorbidities (p = 0.002). In multivariable analysis, respiratory dysfunction was independently associated with COVID-19 hospitalization (odds ratio, 7.66; 95% CI, 2-28; p = 0.002).

Discussion: Respiratory dysfunction is an independent risk factor for severe COVID-19 in PMDs while high disease burden and coexisting comorbidities contribute toward COVID-19-related hospitalization. These findings will enable risk stratification and informed management decisions for this vulnerable population.

PubMed Disclaimer

References

    1. McFarland R, Taylor RW, Turnbull DM. A neurological perspective on mitochondrial disease. Lancet Neurol. 2010;9(8):829-840. - PubMed
    1. Get support if you’re clinically extremely vulnerable to coronavirus (COVID-19). GOV.UK. Accessed August 1, 2021. gov.uk/coronavirus-shielding-support.
    1. Interim Operational Considerations for Implementing the Shielding Approach to Prevent COVID-19 Infections in Humanitarian Settings. Centers for Disease Control and Prevention (CDC). Accessed August 1, 2021. cdc.gov/coronavirus/2019-ncov/global-covid-19/shielding-approach-humanit....
    1. Keddie S, Pakpoor J, Mousele C, et al. . Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome. Brain. 2021;144(2):682-693. - PMC - PubMed
    1. World Health Organization. (2020). Coronavirus Disease 2019 (COVID-19): Situation Report, 61. World Health Organization; 2020. Accessed August 1, 2021. apps.who.int/iris/handle/10665/331605.

Publication types